SOLIGENIX, INC.

Soligenix, Inc. filed a prospectus supplement to increase the maximum aggregate offering amount of its common stock under an At Market Issuance Sales Agreement by an additional $2,500,000. The company had previously sold approximately $6,234,000 of common stock under the same agreement, which originally covered up to $6,406,000.

Soligenix has terminated its HyBryte™ development program after the Phase 3 FLASH2 clinical trial was halted for futility, expecting approximately $70,000 in wind-down charges. Concurrently, the company received a Nasdaq notice for non-compliance with the $1.00 minimum bid price rule, with 180 days to regain compliance by December 7, 2026. Following the program termination, Dr. Richard C. Straube ceased serving as Consulting Chief Medical Officer, with his responsibilities transitioning to Dr. Christopher Pullion. The company is now evaluating strategic options, including M&A and advancing other pipeline programs like dusquetide.

Soligenix, Inc. filed a prospectus supplement on May 28, 2026, to increase the maximum aggregate offering amount of its common stock under an At Market Issuance Sales Agreement with Rodman & Renshaw LLC. The company added an additional $2,956,000 to the offering, bringing the total potential amount to approximately $6,401,000, following previous sales of $3,445,000. This action allows Soligenix to potentially raise more capital through equity sales.

Soligenix, Inc. reported a net loss of $2.82 million for Q1 2026, a slight improvement from $2.95 million in Q1 2025, with basic and diluted net loss per share improving to $(0.28) from $(0.97). However, the company's cash and cash equivalents decreased to $6.03 million from $7.94 million at year-end 2025, and it raised substantial doubt about its ability to continue as a going concern due to insufficient cash for the next 12 months. This comes after the Data Monitoring Committee recommended halting the Phase 3 FLASH2 trial for HyBryte™ (SGX301) in CTCL due to futility in April 2026.